Jinxin Fertility Plans Women's Health-Focused Translational Medicine Platform

MT Newswires Live

2 hours ago

Jinxin Fertility (HKG:1951) plans to develop a translational medicine platform focused mainly on women's health, building on its existing reproductive medicine and research capabilities.

The platform will initially focus on ovarian ageing, weakened ovarian function and other reproductive health conditions, according to a Wednesday Hong Kong bourse filing. Assisted reproductive and related medical services will remain the company's core business.

Jinxin Fertility has entered into a research cooperation memorandum with Ji Weizhi to explore reproductive and developmental biology, regenerative medicine, disease models and translational medicine. The company has also signed a framework agreement with a research animal resources and breeding partner to explore research cohorts and preclinical research infrastructure.

Jinxin Fertility shares fell 2% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/2666557272"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666557272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666557272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 13:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666557272","market":"sh","top_or_hot":-1,"title":"Jinxin Fertility Plans Women's Health-Focused Translational Medicine Platform","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/JXFGF\">Jinxin Fertility</a> (HKG:1951) plans to develop a translational medicine platform focused mainly on women's health, building on its existing reproductive medicine and research capabilities.</p><p>The platform will initially focus on ovarian ageing, weakened ovarian function and other reproductive health conditions, according to a Wednesday Hong Kong bourse filing. Assisted reproductive and related medical services will remain the company's core business.</p><p>Jinxin Fertility has entered into a research cooperation memorandum with Ji Weizhi to explore reproductive and developmental biology, regenerative medicine, disease models and translational medicine. The company has also signed a framework agreement with a research animal resources and breeding partner to explore research cohorts and preclinical research infrastructure.</p><p>Jinxin Fertility shares fell 2% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jinxin Fertility Plans Women's Health-Focused Translational Medicine Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJinxin Fertility Plans Women's Health-Focused Translational Medicine Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-10 13:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/JXFGF\">Jinxin Fertility</a> (HKG:1951) plans to develop a translational medicine platform focused mainly on women's health, building on its existing reproductive medicine and research capabilities.</p><p>The platform will initially focus on ovarian ageing, weakened ovarian function and other reproductive health conditions, according to a Wednesday Hong Kong bourse filing. Assisted reproductive and related medical services will remain the company's core business.</p><p>Jinxin Fertility has entered into a research cooperation memorandum with Ji Weizhi to explore reproductive and developmental biology, regenerative medicine, disease models and translational medicine. The company has also signed a framework agreement with a research animal resources and breeding partner to explore research cohorts and preclinical research infrastructure.</p><p>Jinxin Fertility shares fell 2% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1219","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2666557272","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666557272","pubTimestamp":1789019837,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jinxin Fertility (HKG:1951) plans to develop a translational medicine platform focused mainly on women's health, building on its existing reproductive medicine and research capabilities.The platform w","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1219":"保健护理服务","BK1583":"高瓴概念","BK1597":"三胎概念","01951":"锦欣生殖"},"translate_title":"金鑫生育计划以女性健康为中心的转化医学平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01951":1},"content_text":"Jinxin Fertility (HKG:1951) plans to develop a translational medicine platform focused mainly on women's health, building on its existing reproductive medicine and research capabilities.The platform will initially focus on ovarian ageing, weakened ovarian function and other reproductive health conditions, according to a Wednesday Hong Kong bourse filing. Assisted reproductive and related medical services will remain the company's core business.Jinxin Fertility has entered into a research cooperation memorandum with Ji Weizhi to explore reproductive and developmental biology, regenerative medicine, disease models and translational medicine. The company has also signed a framework agreement with a research animal resources and breeding partner to explore research cohorts and preclinical research infrastructure.Jinxin Fertility shares fell 2% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}